2024
Franzens N, Vancoppenolle J, Vogler S, Retel V, van Harten W. Savings and Transparency: Comparing Publicly Reported Data on Managed Entry Agreements in Europe. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Vogler S, Salcher-Konrad M, Katharina H. Use of strategic approaches in public procurement of medicines: improving affordable patient access to medicines and protecting the environment in 32 European countries. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Schneider P, Salcher-Konrad M, Vogler S. European comparison of prices for off-patent medicines – findings for 16 countries and implications for methodological choices. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Zimmermann N, Schneider P, Paknutova S, Piniazhko O. Evaluation of the external price referencing (EPR) policy for the National Essential Medicines List in Ukraine. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Vogler S, Salcher-Konrad M, Knoll V. Community pharmacy in Austria, England, Estonia and Portugal: Has the COVID-19 pandemic changed the range of pharmacy services offered?. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Salcher-Konrad M, Stefan F, Knoll V, Vogler S. Pharmaceutical care in Austria: A survey on services provided by community pharmacies. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Vogler S, Zimmermann N, Haasis MA, Gombocz M, Knoll V. Approaching two decades of information sharing between competent authorities: Experience from the Pharmaceutical Pricing and Reimbursement Information (PPRI) network. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Vogler S. Increasing prices to ensure availability of medicines? Financial incentives implemented as shortage mitigation policy in PPRI member countries. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Knoll V, Steigenberger C, Fischer S, Vogler S. Made in Europe - assessing the feasibility of reshoring active pharmaceutical ingredient (API) production to Europe. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Leopold C, Vogler S, Suleman F, Wirtz V. Strengthening primary health care through a stronger emphasis on patient and community centered medicines and pharmaceutical services. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
Salcher-Konrad M, Hendrickx A, Schneider P, Zimmermann N. Defining fair prices for new health technologies. In: Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2331920
2023
Schneider P, Salcher-Konrad M, Fischer S, Heindl B, Habl C. HPR148 Bio-Hybrid Medicinal Products: Widening Access or Product Differentiation? Value in Health. 2023;26(12):S279
Vogler S, Steigenberger C. HPR146 Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections. Value in Health. 2023;26(12):S279
Salcher-Konrad M, Zimmermann N, Schneider P, Hendrickx A. HPR164 What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies. Value in Health. 2023;26(12):S282
Steigenberger C, Windisch F, Vogler S. MT7 Barriers and Facilitators for the Use of Point of Care Diagnostics in Patients With Respiratory Tract Infections in Outpatient Care Related to the Peri-Launch Phase. Value in Health. 2023;26(12):S428
Salcher-Konrad M, Vogler S, Habimana K. How to optimise public procurement of medicines? Lessons from a study on public procurement practices in 32 European countries. ATHEA Conference 2023, Vienna, 23 February 2023
2022
Zimmermann N, Vogler S, Haasis MA. HPR117 Meta-Indicators for Analysing Pharmaceutical Systems: The PPRI Indicators. Value in Health. 2022;25(12):S253
Salcher-Konrad M, Habimana K, Vogler S. HPR199 Public Procurement of Medicines: A Taxonomy of Procurement Systems in Europe. Value in Health. 2022;25(12):S269
Vogler S, Zimmermann N. Design of value-added tax on medicines in 41 European countries. European Journal of Public Health. 2022;32(Supplement_3)
Vogler S, Rodríquez-Sánchez DI. Medicines to treat COVID-19 symptoms in short supply: Analysis of shortages registers in Austria, Italy and Spain during the frist wave and fourth wave. European Health Economics Association (EuHEA) conference, Oslo, 5-8 Juliy 2022
Vogler S, Zimmermann N.. Policies to enhance use of biosimilar medicines in 52 countries. Can policy makers draw on lessons from generic policies. European Health Economics Association (EuHEA) conference, Oslo, 5-8 Juliy 2022
2020
Vogler S, Haasis MA, van den Ham R, Suleman F.: Assessment of cross-country collaborations to improve access to medicines in the WHO European Region. In: Abstracts from the EUHEA Conference 2020. Virtual Conference, 09 July 2020
Vogler S, Zimmermann N, Haasis MA.: Comparison of co-payment regulations for medicines in 46 countries. In: Abstracts from the EUHEA Conference 2020. Virtual Conference, 09 July 2020
Schneider P, Rainer L, Zuba M, Vogler S.: An analysis of price developments of biological medicines after patent expiration. In: Abstracts from the EUHEA Conference 2020. Virtual Conference, 09 July 2020
Fischer S, Vogler S.: Drug shortages: The situation in four European countries and their approaches to handle the problem. In: Abstracts from the EUHEA Conference 2020. Virtual Conference, 09 July 2020
2019
Vogler S, Zimmermann N, Haasis MA, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Can pharmaceutical pricing and reimbursement policies make a difference in promoting equitable access to affordable medicines? From diagnosis to sustainable impact. Editorial. 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies: Vienna, Austria. 23-24 October 2019. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Pertile P, Gamba S, Vogler S.: Impact of managed-entry agreements on medicines list prices. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Vogler S, Schneider P.: Impact of the external price referencing methodology (EPR) on medicine prices – Simulation of existing EPR models. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
van den Ham R, Vogler S, Haasis MA, Suleman F.: Together working to improve access to medicines: analysis of cross-country collaborations in Europe. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Zimmermann N, Vogler S, Gombocz M.: Pharmaceutical pricing and reimbursement policies – Comparative analysis in 47 PPRI member countries. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Benslaoui B, Zerhouni MW, Chikhaoui A, Fouila FZB, Habimana K, Hachri H, Bigdeli M, Vogler S, Taoufik J, Nehmi H.: Regulating medicine prices in Morocco - Effects of the medicine price decree 2014 on medicine prices. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Habl C, Németh G, Schneider P.: How the Euripid Collaboration contributes to the affordability of medicines in Europe. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Schneider P, Lepuschütz L, Zimmermann N, Vogler S.: Estimating price developments of biological medicines during market exclusivity. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Schneider P, Vogler S.: Choosing the right medicines for price comparisons - Analysis of prices of pharmaceutical presentations of the same active ingredient. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
Schneider P, Habl C, Németh G.: Ex-post analysis of medicines subject to Managed-Entry-Agreements (MEAs) – a feasible approach for monitoring and price analyses. In: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice 12, 34, 2019
2016
Vogler S, Schneider P, Zimmermann N.: European price comparison of high cost hospital medicines. In: European Journal of Hospital Pharmacy, 23: A163-A164, 2016
Zimmermann N, Gombocz M, Vogler S.: How do Cost-Containment Measures Impact Pharmaceutical Industry?. In: Value in Health, 19: A347– A766, 2016
Vogler S, Schneider P, Gombocz M, Zimmermann N.: Differences In Pricing Policies For Generic And Biosimilar Medicines. In: Value in Health, 19: A347– A766, 2016
Schneider P, Lepuschütz L, Vogler S, Zimmermann N.: Impact Of Changes In The Methodology Of External Price Referencing On Prices. In: Value in Health, 19: A347– A766, 2016
Mayer S, Vogler S, Simon J, Österle A.: Exploring Determinants Of Polypharmacy In The Elderly Population in Austria. In: Value in Health, 19: A347– A766, 2016
DeRooj RH, Frederix GW, Hövels AM, Vogler S.: Relevance And Economic Consequences Of Medicine Waste In Vienna: Analysis Of A Household Garbage Sample. In: Value in Health, 19: A347– A766, 2016
Habl C, Leopold C.: What happens to originator medicines when (generic) followers enter the public market?. In: Value in Health, 19: A347– A766, 2016
Vogler S, Schneider P, Lepuschütz L, Zimmermann N.: How do policy-makers deal with missing price information when they apply External Price Referencing? . In: European Journal of Public Health, 26 (suppl_1): ckw167.069, 2016
Vogler S, Gombocz M, Zimmermann N.: Impacts of tendering for off-patent medicines on access and costs. In: European Journal of Public Health, 26 (suppl_1): ckw167.074, 2016
Vogler S, Österle A, Mayer S.: Changes in socioeconomic determinants of prescribed and non-prescribed medicines use in Austria. In: European Journal of Public Health, 26 (suppl_1): ckw174.163, 2016
2015
Vogler S et al.: Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis. In: Journal of Pharmaceutical Policy and Practice, Volume 8: Supplement 1, 2015
2013
Vogler S, Zimmermann N, Habl C, Leopold C, Dolinar E. OHP-073: Survey of Interface Management Measures Regarding Medicines. In: European Journal of Hospital Pharmacy: Science and Practice, 2013;20(Suppl 1): A161-A, 2013
Vogler S, Zimmermann N, Habl C, Leopold C, Habimana K, Mantel-Teeuwisse A, et al. OHP-084: What Concepts Are Used to Describe the Cooperation Mechanisms Between the Hospital Sector and Primary Care? Analysis of Terminology. In: European Journal of Hospital Pharmacy: Science and Practice , 2013;20(Suppl 1): A165-A, 2013
2011
Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J.: Are Hospital Medicines Prices Influenced by Discounts and Rebates? (PHP22). In: Value in Health, 2011;14(7): A233-A510, 2011